158 related articles for article (PubMed ID: 32219331)
21. CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.
Zeisbrich M; Chevalier N; Sehnert B; Rizzi M; Venhoff N; Thiel J; Voll RE
Front Immunol; 2021; 12():673912. PubMed ID: 34108971
[TBL] [Abstract][Full Text] [Related]
22. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
[TBL] [Abstract][Full Text] [Related]
23. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
[TBL] [Abstract][Full Text] [Related]
24. CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.
Higashi-Kuwata N; Hayashi S; Das D; Kohgo S; Murakami S; Hattori SI; Imoto S; Venzon DJ; Singh K; Sarafianos SG; Tanaka Y; Mitsuya H
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670420
[TBL] [Abstract][Full Text] [Related]
25. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
[TBL] [Abstract][Full Text] [Related]
26. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma.
Liu LL; Zhang SW; Chao X; Wang CH; Yang X; Zhang XK; Wen YL; Yun JP; Luo RZ
Cancer Immunol Immunother; 2021 Feb; 70(2):417-429. PubMed ID: 32770259
[TBL] [Abstract][Full Text] [Related]
27. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer.
Nishi M; Shimada M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Eto S; Yoshimoto T
J Med Invest; 2021; 68(3.4):362-367. PubMed ID: 34759159
[TBL] [Abstract][Full Text] [Related]
28. Anti-HBV drug entecavir ameliorates DSS-induced colitis through PD-L1 induction.
Yamamoto Y; Carreras J; Shimizu T; Kakizaki M; Kikuti YY; Roncador G; Nakamura N; Kotani A
Pharmacol Res; 2022 May; 179():105918. PubMed ID: 35031477
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.
Yasutake Y; Hattori SI; Hayashi H; Matsuda K; Tamura N; Kohgo S; Maeda K; Mitsuya H
Sci Rep; 2018 Jan; 8(1):1624. PubMed ID: 29374261
[TBL] [Abstract][Full Text] [Related]
30. Role of BCLAF-1 in PD-L1 stabilization in response to ionizing irradiation.
Ma Z; Wang H; Meng F; Han Y; Chen Y; Xiao M; Jiang H; Yu Z; Xu B
Cancer Sci; 2021 Oct; 112(10):4064-4074. PubMed ID: 34251713
[TBL] [Abstract][Full Text] [Related]
31. The clinical and prognostic significance of CMTM6/PD-L1 in oncology.
Yaseen MM; Abuharfeil NM; Darmani H
Clin Transl Oncol; 2022 Aug; 24(8):1478-1491. PubMed ID: 35278198
[TBL] [Abstract][Full Text] [Related]
32. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
Long Y; Chen R; Yu X; Tong Y; Peng X; Li F; Hu C; Sun J; Gong L
Cancer Immunol Res; 2023 Feb; 11(2):241-260. PubMed ID: 36484740
[TBL] [Abstract][Full Text] [Related]
33. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
[TBL] [Abstract][Full Text] [Related]
34. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
35. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
[TBL] [Abstract][Full Text] [Related]
36. A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B.
Doğan ÜB; Öztürk AB; Akın MS; Yalaki S; Sayan M
Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():206-9. PubMed ID: 25910308
[TBL] [Abstract][Full Text] [Related]
37. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer.
Liu Y; Li X; Zhang H; Zhang M; Wei Y
Oncogene; 2021 Mar; 40(12):2230-2242. PubMed ID: 33649535
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of hepatitis B virus polymerase by entecavir.
Langley DR; Walsh AW; Baldick CJ; Eggers BJ; Rose RE; Levine SM; Kapur AJ; Colonno RJ; Tenney DJ
J Virol; 2007 Apr; 81(8):3992-4001. PubMed ID: 17267485
[TBL] [Abstract][Full Text] [Related]
39. 4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.
Takamatsu Y; Tanaka Y; Kohgo S; Murakami S; Singh K; Das D; Venzon DJ; Amano M; Higashi-Kuwata N; Aoki M; Delino NS; Hayashi S; Takahashi S; Sukenaga Y; Haraguchi K; Sarafianos SG; Maeda K; Mitsuya H
Hepatology; 2015 Oct; 62(4):1024-36. PubMed ID: 26122273
[TBL] [Abstract][Full Text] [Related]
40. Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.
Xia Y; Stadler D; Lucifora J; Reisinger F; Webb D; Hösel M; Michler T; Wisskirchen K; Cheng X; Zhang K; Chou WM; Wettengel JM; Malo A; Bohne F; Hoffmann D; Eyer F; Thimme R; Falk CS; Thasler WE; Heikenwalder M; Protzer U
Gastroenterology; 2016 Jan; 150(1):194-205. PubMed ID: 26416327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
